Search company, investor...


Incubator/Accelerator | Alive

About Synergen Technologies

Synergen Technologies develops platform polymer technologies that can be utilized for coatings and adhesive applications including coating tabaims to let & capsules to control the time release of drugs and their dosage.

Headquarters Location

2201 West Campbell Park Dr Ste 16

Chicago, Illinois, 60612,

United States



Synergen Technologies Frequently Asked Questions (FAQ)

  • Where is Synergen Technologies's headquarters?

    Synergen Technologies's headquarters is located at 2201 West Campbell Park Dr Ste 16, Chicago.

  • What is Synergen Technologies's latest funding round?

    Synergen Technologies's latest funding round is Incubator/Accelerator.

  • Who are the investors of Synergen Technologies?

    Investors of Synergen Technologies include Chicago Technology Park.

  • Who are Synergen Technologies's competitors?

    Competitors of Synergen Technologies include Intarcia Therapeutics and 4 more.


Compare Synergen Technologies to Competitors

Progression Therapeutics

Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo.

Opal Therapeutics

Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.

NovaDigm Therapeutics

NovaDigm Therapeutics is developing vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company's lead product candidate, NDV-3, is a recombinant glycoprotein vaccine containing a candidal surface antigen, agglutinin-like sequence 3 protein or Als3. Results from a Phase 1 clinical trial demonstrated that a single dose of the NDV-3 vaccine was safe, well-tolerated and induced strong antibody and T-cell immune responses in healthy adults.

PDC Biotech

PDC Biotech is developing a compound, PDC31 which is being developed for the treatment of preterm labor and primary dysmenorrhea. PDC31 is a peptide antagonist of the prostaglandin F2a (FP) receptor, the lead in a series of FP antagonists exclusively licensed to PDC Biotech GmbH from Theratechnologies, (TSX: TH), a Canadian biopharmaceutical company.

Intercept Pharmaceuticals

Intercept Pharmaceuticals engages in the development and commercialization of novel therapeutics in the healthcare sector. Its offerings include the development and delivery of medicines for conditions such as primary biliary cholangitis and severe alcohol-associated hepatitis. The company primarily serves the healthcare industry, with a particular emphasis on liver health. It was founded in 2002 and is based in Morristown, New Jersey.

Cosmo S.p.A.

Cosmo is a fully-integrated speciality pharmaceutical company that aims to become engaged in the market of optimised therapies for selected gastro-intestinal diseases. The company's clinical development pipeline specifically addresses treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn's Disease, as well as for colon infections.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.